130 related articles for article (PubMed ID: 15382678)
1. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase.
Fengqiang W; Boyang S; Yongsu Z
Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
Liu XY; Zhen YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
Wang FQ; Shang BY; Zhen YS
Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitory effects of the immunoconjugate composed of anti-type IV collagenase antibody Fab' fragment and lidamycin on tumor invasion and metastasis].
Feng Y; He HW; Li BW; Zhang ZX; Chen X; Li XF
Yao Xue Xue Bao; 2011 Dec; 46(12):1462-5. PubMed ID: 22375419
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.
Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS
World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
[TBL] [Abstract][Full Text] [Related]
8. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody].
Dai Y; Liu XJ; Zhen YS
Yao Xue Xue Bao; 2006 Jan; 41(1):41-6. PubMed ID: 16683526
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of the growth of hepatoma and hepatic metastasis by pingyangmycin conjugated with Fab' fragment of monoclonal antibody].
Liu X; Shang B; Liu X
Zhonghua Yi Xue Za Zhi; 2001 Feb; 81(4):201-4. PubMed ID: 11798873
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of monoclonal antibody Fab' fragment-containing immunoconjugates.
Liu X; Zhen Y
Chin Med Sci J; 2002 Mar; 17(1):1-6. PubMed ID: 12894876
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor effect of the immunoconjugate composed of antibiotic C1027 and Fab fragment from a monoclonal antibody directed against human hepatoma].
Li JZ; Jiang M; Xue YC; Zhen YS
Yao Xue Xue Bao; 1993; 28(4):260-5. PubMed ID: 8213168
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.
Huang YH; Shang BY; Zhen YS
World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019
[TBL] [Abstract][Full Text] [Related]
14. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
15. A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity.
Jiang L; Yang M; Zhang X; Bao S; Ma L; Fan D; Zhou Y; Xiong D; Zhen Y
J Drug Target; 2016; 24(1):47-57. PubMed ID: 26204323
[TBL] [Abstract][Full Text] [Related]
16. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Shang BY; Shang Y; Zhen YS; Chen SZ
Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
[TBL] [Abstract][Full Text] [Related]
17. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis.
Zhou Z; Zhang J; Zhang Y; Ma G; Su Z
Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
[TBL] [Abstract][Full Text] [Related]
19. [Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts].
Li J; Zhen Y; Yang Z
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Oct; 16(5):328-33. PubMed ID: 7720121
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
